Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) FCF Margin (2016 - 2025)

Cytosorbents (CTSO) has disclosed FCF Margin for 14 consecutive years, with 27.35% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin rose 301.0% year-over-year to 27.35%, compared with a TTM value of 27.09% through Sep 2025, up 2491.0%, and an annual FY2024 reading of 41.33%, up 3006.0% over the prior year.
  • FCF Margin was 27.35% for Q3 2025 at Cytosorbents, down from 13.48% in the prior quarter.
  • Across five years, FCF Margin topped out at 13.37% in Q2 2021 and bottomed at 117.99% in Q1 2022.
  • Average FCF Margin over 5 years is 52.03%, with a median of 54.23% recorded in 2024.
  • The sharpest move saw FCF Margin plummeted -9182bps in 2022, then skyrocketed 7970bps in 2023.
  • Year by year, FCF Margin stood at 65.14% in 2021, then grew by 11bps to 57.71% in 2022, then decreased by -30bps to 75.02% in 2023, then skyrocketed by 65bps to 26.34% in 2024, then fell by -4bps to 27.35% in 2025.
  • Business Quant data shows FCF Margin for CTSO at 27.35% in Q3 2025, 13.48% in Q2 2025, and 42.6% in Q1 2025.